Individuals' experiences in genetic counseling and predictive testing for familial amyotrophic lateral sclerosis

被引:2
|
作者
Steigerwald, Connolly G. [1 ,2 ]
Bertolini, Carina [1 ]
McElhiney, Martin [3 ,4 ]
Bergner, Amanda L. [1 ,5 ]
Harms, Matthew B. [6 ]
Harrington, Elizabeth A. [1 ,6 ]
机构
[1] Columbia Univ, Vagelos Coll Phys & Surg, Genet Counseling Grad Program, New York, NY USA
[2] NYU Grossman Sch Med, Dept Neurol, Div Neurogenet, New York, NY 10016 USA
[3] Columbia Univ, Vagelos Coll Phys & Surg, Dept Psychiat, New York, NY USA
[4] New York State Psychiat Inst & Hosp, New York, NY USA
[5] Columbia Univ, Vagelos Coll Phys & Surg, Dept Genet & Dev, New York, NY USA
[6] Columbia Univ, Vagelos Coll Phys & Surg, Dept Neurol, New York, NY USA
关键词
decision making; genetic counseling; lived experience; predictive genetic testing; psychosocial; HUNTINGTONS-DISEASE; PSYCHOLOGICAL IMPACT; MUTATIONS; PENETRANCE; PROGNOSIS; DECISION; UPDATE; ALS;
D O I
10.1002/jgc4.1890
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
As clinical genetic testing in the amyotrophic lateral sclerosis (ALS) diagnostic setting increases, the identification of at-risk family members has also expanded. No practice guidelines specifically for predictive genetic testing exist, and few studies about the psychological impacts of testing in this subgroup have occurred, limiting the ability to tailor recommendations and counseling in this community. We surveyed asymptomatic individuals at risk for inheriting an ALS-associated gene mutation. The 80-question survey was designed using a combination of validated measures (General Anxiety Disorder; FACToR; Decision Regret Scale) and original items. Ninety participants completed the survey, including those who completed predictive genetic testing (N = 42) and those who did not (N = 48). Gene positive individuals experienced greater negativity, uncertainty, and overall psychological impairment (p = 0.002; p < 0.001; p = 0.001). Individuals who had not undergone testing reported thinking about their risk multiple times per day and experiencing more decisional regret than those who tested (p = 0.006). In terms of decision-making, being prepared for potential clinical drug trials was a more important potential benefit among those who underwent testing (p = 0.026). Participants valuing preparedness for clinical drug trials supports the concept that genetic testing for ALS will increase as research in gene-targeted therapeutics progresses. This study describes factors relevant to the genetic testing decision-making process and adaptation to results from the perspective of at-risk individuals, which can ultimately guide genetic counseling practice in this population.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Genetic testing for monogenic forms of motor neuron disease/amyotrophic lateral sclerosis in unaffected family members
    Howard, Jade
    Chaouch, Amina
    Douglas, Andrew G. L.
    Macleod, Rhona
    Roggenbuck, Jennifer
    McNeill, Alisdair
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2025, 33 (01) : 7 - 13
  • [22] Transitions in Amyotrophic Lateral Sclerosis: Patient and Caregiver Experiences
    Munan, Matthew
    Luth, Westerly
    Genuis, Shelagh K.
    Johnston, Wendy S. W.
    MacIntyre, Erika
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2021, 48 (04) : 496 - 503
  • [23] Advances in the genetic classification of amyotrophic lateral sclerosis
    Cooper-Knock, Johnathan
    Harvey, Calum
    Zhang, Sai
    Moll, Tobias
    Timpanaro, Ilia Sarah
    Kenna, Kevin P.
    Iacoangeli, Alfredo
    Veldink, Jan H.
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (05) : 756 - 764
  • [24] Estimated Familial Amyotrophic Lateral Sclerosis Proportion
    Barberio, Julie
    Lally, Cathy
    Kupelian, Varant
    Hardiman, Orla
    Flanders, W. Dana
    NEUROLOGY-GENETICS, 2023, 9 (06)
  • [25] Reproductive decision-making among individuals at risk for familial amyotrophic lateral sclerosis
    Hartzfeld, Deborah E. H.
    Siddique, Nailah
    Victorson, David
    O'Neill, Suzanne
    Kinsley, Lisa
    Siddique, Teepu
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2015, 16 (1-2) : 114 - 119
  • [26] The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis
    Salmon, Kristiana
    Kiernan, Matthew C.
    Kim, Seung H.
    Andersen, Peter M.
    Chio, Adriano
    van den Berg, Leonard H.
    Van Damme, Philip
    Al-Chalabi, Ammar
    Lillo, Patricia
    Andrews, Jinsy A.
    Genge, Angela
    BRAIN, 2022, 145 (04) : 1207 - 1210
  • [27] Mitochondrial dysfunction in familial amyotrophic lateral sclerosis
    Faes, Liesbeth
    Callewaert, Geert
    JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2011, 43 (06) : 587 - 592
  • [28] Genetic Landscape of Amyotrophic Lateral Sclerosis in Czech Patients
    Baumgartner, Daniel
    Musova, Zuzana
    Zidkova, Jana
    Hedvicakova, Petra
    Vlckova, Eva
    Joppekova, Lubica
    Kramarova, Tereza
    Fajkusova, Lenka
    Stranecky, Viktor
    Geryk, Jan
    Votypka, Pavel
    Mazanec, Radim
    JOURNAL OF NEUROMUSCULAR DISEASES, 2024, 11 (05) : 1035 - 1048
  • [29] Genetic studies of Russian patients with amyotrophic lateral sclerosis
    Lysogorskaia, Elena V.
    Abramycheva, Nataliya Yu
    Zakharova, Mariya N.
    Stepanova, Mariya S.
    Moroz, Anna A.
    Rossokhin, Alexey V.
    Illarioshkin, Sergey N.
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2016, 17 (1-2) : 135 - 141
  • [30] Genetic and clinical analysis of OPTN in amyotrophic lateral sclerosis
    Xiao, Yi
    Tan, Yushan
    Li, Chunyu
    Wei, Qianqian
    Jiang, Qirui
    Wang, Shichan
    Yang, Tianmi
    Lin, Junyu
    Zhang, Lingyu
    Shang, Huifang
    JOURNAL OF MEDICAL GENETICS, 2025, : 242 - 248